Evopoint Entered into a Clinical Trial Collaboration with MSD to Evaluate XNW5004 with Keytruda for Solid Tumors
- Both companies have joined forces to evaluate Evopoint’s XNW5004 (an EZH2-inhibitor) in combination with MSD’s Keytruda (pembrolizumab) in a P-Ib/II clinical trial analysing Chinese patients with solid tumors
- As per the agreement, Evopoint will sponsor the P-Ib/II clinical trial, MSD will provide Keytruda & Evopoint will retain the worldwide rights to XNW5004. The P-Ib/II clinical trial evaluates the RP2D dose of XNW5004 to be used to evaluate the safety & efficacy of XNW5004 + Keytruda in patients with solid tumors
- Previously in preclinical studies, XNW5004 depicted a significant anti-tumor activity & safety in varying liquid & solid tumor models whereas in P-I clinical trial, XNW5004 showed remarkable single-agent efficacy & safety in patients with lymphoma
Ref: Businesswire | Image: Merck
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.